Research programme: antibody-drug conjugates - Ambrx/Astellas Pharma
Latest Information Update: 13 Mar 2024
Price :
$50 *
At a glance
- Originator Ambrx
- Developer Ambrx; Astellas Pharma
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 26 Nov 2015 Preclinical trials in Cancer in USA (Parenteral)